Much Ado About Nothing Much With Atara's MS Hopeful
Interim Analysis On ATA188 Reveals Little
Executive Summary
Investors and most analysts were not impressed with a much-anticipated Phase II update on Atara’s allogeneic T-cell immunotherapy which could be transformational as a treatment for multiple sclerosis, but some observers believe the slump in the firm’s stock was not merited.
You may also be interested in...
A Master Of Firsts: Pascal Touchon On Atara Bio And The Maturing Cell Therapy Ecosystem
Having led the way to regulatory approval for Kymriah and now Ebvallo, Atara CEO Pascal Touchon reflects on the evolution of cell therapy and what his company is doing differently.
Finance Watch: The Job Cuts Keep Coming As Companies Try To Conserve Cash
Restructuring Updates: Homology implemented modest job cuts as it ended a gene therapy trial, while ProQR revealed its second round of layoffs this year and Synthetic Biologics shifted focus to oncolytic virus pipeline. Also, Bolt, MacroGenics and others deprioritized programs in their Q2 updates.
Pierre Fabre Fights Off Rivals For Rights To Atara's Allogeneic T-Cell Therapy
After paying $45m upfront, the French firm has beaten off considerable competition to seal the European, Middle East and African rights to tabelecleucel which will be filed next month for Epstein-Barr virus-positive post-transplant lymphoproliferative disease.